Effects  ||| S:0 E:8 ||| NNS
of  ||| S:8 E:11 ||| IN
flunixin  ||| S:11 E:20 ||| NN
on  ||| S:20 E:23 ||| IN
cardiorespiratory ||| S:23 E:40 ||| NN
,  ||| S:40 E:42 ||| ,
plasma  ||| S:42 E:49 ||| JJ
lactate  ||| S:49 E:57 ||| NN
and  ||| S:57 E:61 ||| CC
stride  ||| S:61 E:68 ||| JJ
length  ||| S:68 E:75 ||| NN
responses  ||| S:75 E:85 ||| NNS
to  ||| S:85 E:88 ||| TO
intense  ||| S:88 E:96 ||| JJ
treadmill  ||| S:96 E:106 ||| JJ
exercise  ||| S:106 E:115 ||| NN
in  ||| S:115 E:118 ||| IN
Standardbred  ||| S:118 E:131 ||| NNP
trotters  ||| S:131 E:140 ||| NN
Since  ||| S:140 E:146 ||| IN
nonsteroidal  ||| S:146 E:159 ||| JJ
anti-inflammatory  ||| S:159 E:177 ||| JJ
drugs ||| S:177 E:182 ||| NNS
,  ||| S:182 E:184 ||| ,
such  ||| S:184 E:189 ||| JJ
as  ||| S:189 E:192 ||| IN
flunixin ||| S:192 E:200 ||| NN
,  ||| S:200 E:202 ||| ,
on  ||| S:202 E:205 ||| IN
account  ||| S:205 E:213 ||| NN
of  ||| S:213 E:216 ||| IN
their  ||| S:216 E:222 ||| PRP$
anti-inflammatory  ||| S:222 E:240 ||| JJ
and  ||| S:240 E:244 ||| CC
analgesic  ||| S:244 E:254 ||| JJ
properties ||| S:254 E:264 ||| NNS
,  ||| S:264 E:266 ||| ,
are  ||| S:266 E:270 ||| VBP
used  ||| S:270 E:275 ||| VBN
in  ||| S:275 E:278 ||| IN
both  ||| S:278 E:283 ||| DT
racing  ||| S:283 E:290 ||| NN
and  ||| S:290 E:294 ||| CC
equestrian  ||| S:294 E:305 ||| JJ
sport  ||| S:305 E:311 ||| NN
horses ||| S:311 E:317 ||| NNS
,  ||| S:317 E:319 ||| ,
the  ||| S:319 E:323 ||| DT
question  ||| S:323 E:332 ||| NN
has  ||| S:332 E:336 ||| VBZ
been  ||| S:336 E:341 ||| VBN
raised  ||| S:341 E:348 ||| VBN
as  ||| S:348 E:351 ||| RB
to  ||| S:351 E:354 ||| TO
whether  ||| S:354 E:362 ||| IN
these  ||| S:362 E:368 ||| DT
drugs  ||| S:368 E:374 ||| NNS
affect  ||| S:374 E:381 ||| VBP
the  ||| S:381 E:385 ||| DT
physiological  ||| S:385 E:399 ||| JJ
responses  ||| S:399 E:409 ||| NNS
to  ||| S:409 E:412 ||| TO
exercise  ||| S:412 E:421 ||| VB
and  ||| S:421 E:425 ||| CC
thus  ||| S:425 E:430 ||| RB
performance  ||| S:430 E:442 ||| NN
potential ||| S:442 E:451 ||| NN
.  ||| S:451 E:453 ||| .
The  ||| S:453 E:457 ||| DT
aims  ||| S:457 E:462 ||| NNS
of  ||| S:462 E:465 ||| IN
this  ||| S:465 E:470 ||| DT
investigation  ||| S:470 E:484 ||| NN
were  ||| S:484 E:489 ||| VBD
to  ||| S:489 E:492 ||| TO
study  ||| S:492 E:498 ||| VB
the  ||| S:498 E:502 ||| DT
effects  ||| S:502 E:510 ||| NNS
of  ||| S:510 E:513 ||| IN
flunixin  ||| S:513 E:522 ||| NN
on  ||| S:522 E:525 ||| IN
cardiorespiratory ||| S:525 E:542 ||| NN
,  ||| S:542 E:544 ||| ,
metabolic  ||| S:544 E:554 ||| NN
and  ||| S:554 E:558 ||| CC
locomotor  ||| S:558 E:568 ||| JJ
parameters  ||| S:568 E:579 ||| NNS
in  ||| S:579 E:582 ||| IN
horses  ||| S:582 E:589 ||| NNS
during  ||| S:589 E:596 ||| IN
intense  ||| S:596 E:604 ||| JJ
treadmill  ||| S:604 E:614 ||| JJ
exercise ||| S:614 E:622 ||| NN
.  ||| S:622 E:624 ||| .
Six  ||| S:624 E:628 ||| CD
Standardbred  ||| S:628 E:641 ||| JJ
trotters  ||| S:641 E:650 ||| NN
underwent  ||| S:650 E:660 ||| VBD
an  ||| S:660 E:663 ||| DT
incremental  ||| S:663 E:675 ||| JJ
treadmill  ||| S:675 E:685 ||| JJ
exercise  ||| S:685 E:694 ||| NN
test  ||| S:694 E:699 ||| NN
to  ||| S:699 E:702 ||| TO
fatigue ||| S:702 E:709 ||| VB
,  ||| S:709 E:711 ||| ,
without  ||| S:711 E:719 ||| IN
drug  ||| S:719 E:724 ||| NN
and  ||| S:724 E:728 ||| CC
then  ||| S:728 E:733 ||| RB
after  ||| S:733 E:739 ||| IN
administration  ||| S:739 E:754 ||| NN
of  ||| S:754 E:757 ||| IN
flunixin  ||| S:757 E:766 ||| JJ
meglumine  ||| S:766 E:776 ||| NNS
( ||| S:776 E:777 ||| -LRB-
1.1  ||| S:777 E:781 ||| FW
mg ||| S:781 E:783 ||| FW
/ ||| S:783 E:784 ||| FW
kg  ||| S:784 E:787 ||| FW
bwt  ||| S:787 E:791 ||| FW
i.m. ||| S:791 E:795 ||| FW
) ||| S:795 E:796 ||| -RRB-
.  ||| S:796 E:798 ||| .
Heart  ||| S:798 E:804 ||| NN
rate  ||| S:804 E:809 ||| NN
( ||| S:809 E:810 ||| -LRB-
HR ||| S:810 E:812 ||| NNP
) ||| S:812 E:813 ||| -RRB-
,  ||| S:813 E:815 ||| ,
oxygen  ||| S:815 E:822 ||| NN
uptake  ||| S:822 E:829 ||| NNS
and  ||| S:829 E:833 ||| CC
stride  ||| S:833 E:840 ||| JJ
length  ||| S:840 E:847 ||| NN
were  ||| S:847 E:852 ||| VBD
measured  ||| S:852 E:861 ||| VBN
and  ||| S:861 E:865 ||| CC
venous  ||| S:865 E:872 ||| JJ
blood  ||| S:872 E:878 ||| NN
samples  ||| S:878 E:886 ||| NNS
drawn  ||| S:886 E:892 ||| VBN
repeatedly  ||| S:892 E:903 ||| RB
during  ||| S:903 E:910 ||| IN
the  ||| S:910 E:914 ||| DT
test ||| S:914 E:918 ||| NN
.  ||| S:918 E:920 ||| .
Heart  ||| S:920 E:926 ||| NN
rates  ||| S:926 E:932 ||| NNS
were  ||| S:932 E:937 ||| VBD
found  ||| S:937 E:943 ||| VBN
to  ||| S:943 E:946 ||| TO
be  ||| S:946 E:949 ||| VB
significantly  ||| S:949 E:963 ||| RB
higher  ||| S:963 E:970 ||| JJR
at  ||| S:970 E:973 ||| IN
submaximal  ||| S:973 E:984 ||| JJ
speeds ||| S:984 E:990 ||| NNS
,  ||| S:990 E:992 ||| ,
while  ||| S:992 E:998 ||| IN
the  ||| S:998 E:1002 ||| DT
velocity  ||| S:1002 E:1011 ||| NN
causing  ||| S:1011 E:1019 ||| VBG
a  ||| S:1019 E:1021 ||| DT
HR  ||| S:1021 E:1024 ||| NNP
of  ||| S:1024 E:1027 ||| IN
200  ||| S:1027 E:1031 ||| CD
beats ||| S:1031 E:1036 ||| CD
/ ||| S:1036 E:1037 ||| CD
min  ||| S:1037 E:1041 ||| NNS
was  ||| S:1041 E:1045 ||| VBD
significantly  ||| S:1045 E:1059 ||| RB
decreased  ||| S:1059 E:1069 ||| VBN
after  ||| S:1069 E:1075 ||| IN
treatment  ||| S:1075 E:1085 ||| NN
with  ||| S:1085 E:1090 ||| IN
flunixin ||| S:1090 E:1098 ||| NN
.  ||| S:1098 E:1100 ||| .
Maximal  ||| S:1100 E:1108 ||| NNP
HR  ||| S:1108 E:1111 ||| NNP
and  ||| S:1111 E:1115 ||| CC
plasma  ||| S:1115 E:1122 ||| JJ
lactate  ||| S:1122 E:1130 ||| JJ
concentration  ||| S:1130 E:1144 ||| NN
5  ||| S:1144 E:1146 ||| CD
min  ||| S:1146 E:1150 ||| NN
after  ||| S:1150 E:1156 ||| IN
exercise  ||| S:1156 E:1165 ||| NN
were  ||| S:1165 E:1170 ||| VBD
unchanged  ||| S:1170 E:1180 ||| JJ
after  ||| S:1180 E:1186 ||| IN
medication ||| S:1186 E:1196 ||| NN
.  ||| S:1196 E:1198 ||| .
Flunixin  ||| S:1198 E:1207 ||| NNP
caused  ||| S:1207 E:1214 ||| VBD
higher  ||| S:1214 E:1221 ||| JJR
plasma  ||| S:1221 E:1228 ||| JJ
lactate  ||| S:1228 E:1236 ||| JJ
concentrations  ||| S:1236 E:1251 ||| NNS
at  ||| S:1251 E:1254 ||| IN
all  ||| S:1254 E:1258 ||| DT
speeds  ||| S:1258 E:1265 ||| NNS
and  ||| S:1265 E:1269 ||| CC
the  ||| S:1269 E:1273 ||| DT
lactate  ||| S:1273 E:1281 ||| JJ
threshold  ||| S:1281 E:1291 ||| NN
was  ||| S:1291 E:1295 ||| VBD
decreased ||| S:1295 E:1304 ||| VBN
,  ||| S:1304 E:1306 ||| ,
compared  ||| S:1306 E:1315 ||| VBN
with  ||| S:1315 E:1320 ||| IN
baseline  ||| S:1320 E:1329 ||| NN
values ||| S:1329 E:1335 ||| NNS
.  ||| S:1335 E:1337 ||| .
Oxygen  ||| S:1337 E:1344 ||| NNP
uptake  ||| S:1344 E:1351 ||| VBD
levelled  ||| S:1351 E:1360 ||| VBN
off  ||| S:1360 E:1364 ||| RP
at  ||| S:1364 E:1367 ||| IN
the  ||| S:1367 E:1371 ||| DT
highest  ||| S:1371 E:1379 ||| JJS
velocities  ||| S:1379 E:1390 ||| NN
and  ||| S:1390 E:1394 ||| CC
did  ||| S:1394 E:1398 ||| VBD
not  ||| S:1398 E:1402 ||| RB
change  ||| S:1402 E:1409 ||| VB
after  ||| S:1409 E:1415 ||| IN
flunixin  ||| S:1415 E:1424 ||| JJ
treatment ||| S:1424 E:1433 ||| NN
.  ||| S:1433 E:1435 ||| .
Stride  ||| S:1435 E:1442 ||| JJ
length  ||| S:1442 E:1449 ||| NN
was  ||| S:1449 E:1453 ||| VBD
increased  ||| S:1453 E:1463 ||| VBN
after  ||| S:1463 E:1469 ||| IN
treatment ||| S:1469 E:1478 ||| NN
,  ||| S:1478 E:1480 ||| ,
although  ||| S:1480 E:1489 ||| IN
not  ||| S:1489 E:1493 ||| RB
at  ||| S:1493 E:1496 ||| IN
the  ||| S:1496 E:1500 ||| DT
highest  ||| S:1500 E:1508 ||| JJS
velocities ||| S:1508 E:1518 ||| NN
.  ||| S:1518 E:1520 ||| .
The  ||| S:1520 E:1524 ||| DT
increased  ||| S:1524 E:1534 ||| JJ
HR  ||| S:1534 E:1537 ||| NNP
and  ||| S:1537 E:1541 ||| CC
lactate  ||| S:1541 E:1549 ||| JJ
responses  ||| S:1549 E:1559 ||| NNS
to  ||| S:1559 E:1562 ||| TO
exercise  ||| S:1562 E:1571 ||| VB
after  ||| S:1571 E:1577 ||| IN
flunixin  ||| S:1577 E:1586 ||| JJ
treatment  ||| S:1586 E:1596 ||| NN
indicate  ||| S:1596 E:1605 ||| VBP
that  ||| S:1605 E:1610 ||| IN
it  ||| S:1610 E:1613 ||| PRP
does  ||| S:1613 E:1618 ||| VBZ
influence  ||| S:1618 E:1628 ||| NN
physiological  ||| S:1628 E:1642 ||| NN
responses ||| S:1642 E:1651 ||| NNS
,  ||| S:1651 E:1653 ||| ,
but  ||| S:1653 E:1657 ||| CC
does  ||| S:1657 E:1662 ||| VBZ
not  ||| S:1662 E:1666 ||| RB
improve  ||| S:1666 E:1674 ||| VB
the  ||| S:1674 E:1678 ||| DT
performance  ||| S:1678 E:1690 ||| NN
potential  ||| S:1690 E:1700 ||| NN
of  ||| S:1700 E:1703 ||| IN
clinically  ||| S:1703 E:1714 ||| JJ
healthy  ||| S:1714 E:1722 ||| JJ
horses ||| S:1722 E:1728 ||| NNS
.  ||| S:1728 E:1730 ||| .
However ||| S:1730 E:1737 ||| RB
,  ||| S:1737 E:1739 ||| ,
the  ||| S:1739 E:1743 ||| DT
lengthened  ||| S:1743 E:1754 ||| JJ
stride  ||| S:1754 E:1761 ||| NN
during  ||| S:1761 E:1768 ||| IN
submaximal  ||| S:1768 E:1779 ||| JJ
exercise  ||| S:1779 E:1788 ||| NN
after  ||| S:1788 E:1794 ||| IN
medication  ||| S:1794 E:1805 ||| NN
could  ||| S:1805 E:1811 ||| MD
imply  ||| S:1811 E:1817 ||| VB
undetected  ||| S:1817 E:1828 ||| JJ
subclinical  ||| S:1828 E:1840 ||| JJ
lameness ||| S:1840 E:1848 ||| NN
,  ||| S:1848 E:1850 ||| ,
masked  ||| S:1850 E:1857 ||| VBN
in  ||| S:1857 E:1860 ||| IN
some  ||| S:1860 E:1865 ||| DT
of  ||| S:1865 E:1868 ||| IN
the  ||| S:1868 E:1872 ||| DT
horses ||| S:1872 E:1878 ||| NNS
,  ||| S:1878 E:1880 ||| ,
i.e.  ||| S:1880 E:1885 ||| VBZ
they  ||| S:1885 E:1890 ||| PRP
have  ||| S:1890 E:1895 ||| VBP
performed  ||| S:1895 E:1905 ||| VBN
with  ||| S:1905 E:1910 ||| IN
a  ||| S:1910 E:1912 ||| DT
longer  ||| S:1912 E:1919 ||| JJR
stride  ||| S:1919 E:1926 ||| NN
at  ||| S:1926 E:1929 ||| IN
the  ||| S:1929 E:1933 ||| DT
cost  ||| S:1933 E:1938 ||| NN
of  ||| S:1938 E:1941 ||| IN
a  ||| S:1941 E:1943 ||| DT
higher  ||| S:1943 E:1950 ||| JJR
heart  ||| S:1950 E:1956 ||| NN
rate  ||| S:1956 E:1961 ||| NN
and  ||| S:1961 E:1965 ||| CC
an  ||| S:1965 E:1968 ||| DT
increased  ||| S:1968 E:1978 ||| JJ
lactate  ||| S:1978 E:1986 ||| JJ
concentration ||| S:1986 E:1999 ||| NN
.  ||| S:1999 E:2001 ||| .
